Donor immune cells take on autoimmune kidney disease in early trial
NCT ID NCT06557265
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental therapy called NKX019, which uses specially engineered immune cells from donors to target and calm overactive immune cells in people with lupus nephritis or primary membranous nephropathy. The trial involves 120 adults who have not responded to standard treatments. The main goals are to check safety and find the right dose, with early signs of kidney improvement also being tracked.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NKX019 (a type of immune cell therapy called CAR NK cells, made from donor cells, targeting CD19)
- What this could lead to
- If successful, this could point toward a new treatment option for people with lupus nephritis or membranous nephropathy that doesn't respond to standard therapies.
- What could go wrong
- This is an early phase 1/2 trial with only 120 participants, so it's too soon to know if it works or is safe. There are risks from the chemotherapy used to prepare the body and from the cell therapy itself, including immune reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLOMERULONEPHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Nkarta Investigational Site
RECRUITINGLittle Rock, Arkansas, 72201, United States
-
Nkarta Investigational Site
RECRUITINGTustin, California, 92780, United States
-
Nkarta Investigational Site
RECRUITINGGainesville, Florida, 32601, United States
-
Nkarta Investigational Site
WITHDRAWNMiami, Florida, 33133, United States
-
Nkarta Investigational Site
RECRUITINGPlantation, Florida, 33317, United States
-
Nkarta Investigational Site
RECRUITINGTampa, Florida, 33602, United States
-
Nkarta Investigational Site
RECRUITINGAtlanta, Georgia, 30303, United States
-
Nkarta Investigational Site
RECRUITINGChicago, Illinois, 60612, United States
-
Nkarta Investigational Site
RECRUITINGNew Orleans, Louisiana, 70112, United States
-
Nkarta Investigational Site
RECRUITINGWorcester, Massachusetts, 01608, United States
-
Nkarta Investigational Site
RECRUITINGAnn Arbor, Michigan, 48109, United States
-
Nkarta Investigational Site
RECRUITINGSummit, New Jersey, 07901, United States
-
Nkarta Investigational Site
RECRUITINGNew York, New York, 10007, United States
-
Nkarta Investigational Site
RECRUITINGStony Brook, New York, 11794, United States
-
Nkarta Investigational Site
RECRUITINGSyracuse, New York, 13202, United States
-
Nkarta Investigational Site
RECRUITINGDallas, Texas, 75201, United States
-
Nkarta Investigational Site
RECRUITINGHouston, Texas, 77002, United States
-
Nkarta Investigational Site
RECRUITINGParkville, Victoria, 3050, Australia
-
Nkarta Investigational Site
RECRUITINGManati, 00674, Puerto Rico
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells tackle a tough kidney disease?
- A simple blood test may reveal kidney damage in lupus — no biopsy needed?
- Can a Three-Drug combo quiet lupus kidney flares?
- Can a smarter antibody outsmart a kidney disease that resists standard treatment?
- Can engineered immune cells tame autoimmune kidney disease?
- Can a single infusion tame tough lupus?